ProPath Adds New Test for the Detection of Synovial Sarcoma
DALLAS--(BUSINESS WIRE)-- ProPath’s Immunohistochemistry (IHC) laboratory has obtained a significant new addition to its library of over 300 antibody tests.
Cary J. Buresh, M.D., ProPath’s Director of Immunohistochemistry, stated, “I am happy to announce the addition of SS18-SSX to our antibody library. It is a fusion-specific antibody that is highly sensitive (95%) and specific (100%) for the detection of synovial sarcoma.”
Synovial sarcoma is a rare form of cancer found in different types of soft tissue, such as muscle or ligaments. It’s often seen in the arm, leg, or foot, and near joints such as the wrist or ankle. It can also form in the lung or abdomen.
The SS18-SSX test from ProPath will help doctors quickly identify if their patient has synovial sarcoma. For more information about ProPath’s IHC laboratory, please go to www.ProPath.com.
ProPath is the largest, nationwide, 100 percent physician-owned pathology practice in the United States. Led by a team of world-class physicians and scientists, ProPath routinely diagnoses cases from 45 states and several foreign countries. Its 500 employees reside in 10 states and staff lab facilities in two states. For 54 years, ProPath’s mission has been to provide patient-centered, high quality and effective medical diagnostics, prognostics and research that creates better patient outcomes.
Douglas Kale, Marketing Manager